IQVIA Holdings Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IQV research report →
Range $240 – $346
Price Chart
About the company
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
- CEO
- Ari Bousbib
- IPO
- 2013
- Employees
- 94,000
- HQ
- Durham, NC, US
AI snapshot
Six angles, distilled from the data.
The stock remains in a constructive multi-month uptrend, trading above its 200-day average of 211.03 and only modestly above the 50-day at 267.41. It sits well below the 52-week high of 284.50, so the setup is strong but not yet stretched at the top of the range.
Street sentiment stays favorable: consensus is Buy with a 4.7 score and a $291.33 target, above the recent close. Recent calls have leaned higher, with multiple target raises into the $300-$346 range and only one notable downgrade to Equal-Weight since midyear.
IQVIA has a clean beat streak, with 8 straight EPS beats and the latest quarter topping estimates by 0.3%. Next-year EPS is modeled at 14.20 versus 8.22 TTM, so shareholders should watch whether margin gains and revenue growth keep supporting that step-up.
The pattern is net selling, but most of the activity is automatic or administrative rather than clear discretionary conviction. The main signal is repeated officer sales in late July, August, September, and November, while several November director awards look routine and do not offset the selling trend.
Profitability is solid and improving from a quality standpoint, with gross margin at 33.1%, operating margin at 13.9%, and net margin at 8.1%. Revenue grew 8% year over year and earnings grew 8.8%, while free cash flow reached $3.26 billion, or $19.76 per share, in fiscal 2025.
IQVIA screens as a premium life sciences tools and services name, supported by consistent execution and a strong cash profile. The shares trade at 21.86x earnings, a valuation that reflects quality but still leaves room for debate versus faster-growing peers and the broader healthcare services group.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $40.51B
- P/E
- 30.99
- Fwd P/E
- 18.97
- PEG
- 2.35
- P/S
- 2.45
- P/B
- 6.38
- EV/EBITDA
- 15.65
- Div Yield
- 0.00%
- Gross Margin
- 33.07%
- Op Margin
- 12.82%
- Net Margin
- 8.05%
- ROE
- 21.82%
- ROIC
- 7.83%
Latest fiscal year · YoY change
- Revenue
- $16.31B+5.9%
- Gross Profit
- $5.43B+1.0%
- Op Income
- $2.18B
- Net Income
- $1.36B-0.9%
- EPS
- $7.91+4.5%
- OCF Growth
- -2.3%
- FCF Growth
- -3.0%
- 52W High
- $284.50
- 52W Low
- $154.50
- 50D MA
- $267.20
- 200D MA
- $211.84
- Beta
- 1.16
- RSI (14)
- 32
- Avg Volume
- 1.45M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
IQVIA posted an across-the-board beat in Q3, with accelerating organic growth, stronger bookings, margin expansion, and a raised full-year 2026 outlook.· October 27, 2026
- Q3 revenue was $4.43 billion, up 8% reported and 8.6% constant currency; organic growth was about 6%.
- Adjusted EBITDA was $1.008 billion, up 8.7% year over year, with adjusted EBITDA margin up 20 basis points.
- Adjusted diluted EPS was $3.34, up 11.3% year over year, and exceeded the high end of guidance.
- Clinical bookings were particularly strong at $3.2 billion, up 15% year over year, with book-to-bill at 1.2 and last-12-month bookings up 14% to $11.7 billion.
- Management said AI adoption is helping win work and improve productivity, and it raised full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted EPS.
IQVIA reported third-quarter revenue of $4.43 billion, up 8% reported and 8.6% at constant currency, with organic revenue growth of approximately 6%. Commercial Solutions revenue was $1.79 billion, up 6.9% reported, and R&D Solutions revenue was $2.64 billion, up 8.7% reported. Adjusted EBITDA was $1.008 billion, up 8.7% year over year, with adjusted EBITDA margin expanding 20 basis points. GAAP net income was $350 million and GAAP diluted EPS was $2.10; adjusted net income was $557 million and adjusted diluted EPS was $3.34, up 11.3% year over year. Free cash flow was $667 million, CFO was $825 million, capex was $158 million, cash and equivalents were $2.249 billion, gross debt was $16.067 billion, and net leverage was 3.45x trailing 12-month adjusted EBITDA. On guidance, IQVIA raised full-year 2026 revenue guidance to $17.350 billion to $17.5 billion, implying 6.4% to 7.3% growth; adjusted EBITDA guidance to $4.025 billion to $4.055 billion, with margins expected to be about 23.2%; and adjusted diluted EPS guidance to $12.90 to $13.00. Management also said Q4 net interest expense should be around $210 million, D&A just over $160 million, and weighted average diluted shares about 169 million.
Ari Bousbib framed the quarter as evidence that IQVIA is outperforming an improving market, saying organic growth accelerated meaningfully in both commercial and clinical and that win rates improved. He emphasized that AI is becoming a real differentiator, with 415 agents deployed to date and customer adoption deepening across clinical and commercial workflows. His tone was confident and expansive, repeatedly pointing to stronger demand, stronger bookings, and the company’s ability to use data, context, and domain expertise to convert AI into practical value for clients.
Michael Fedock focused on the hard numbers: revenue of $4.43 billion, adjusted EBITDA of $1.008 billion, adjusted diluted EPS of $3.34, and free cash flow of $667 million. He highlighted that pass-throughs were about a 70 basis point headwind to gross margin, while the company still expanded adjusted EBITDA margin by 20 basis points, and he also cited the $2.1 billion backlog adjustment tied to inactive trials, which he said did not affect 2026 guidance, bookings, or next-12-month revenue from backlog. On capital structure, he pointed to $2.249 billion of cash, $16.067 billion of gross debt, net debt of $13.818 billion, and leverage of 3.45x.
Analysts pressed management on whether AI changes how IQVIA can monetize its differentiation, whether bookings strength was seasonal or broad-based, the impact of pass-through mix on margins, and the reason for the $2.1 billion backlog scrub. Management said AI is mainly an incremental revenue opportunity on the commercial side and a workflow/timeline accelerator in R&D, rather than a direct pricing reset, though it should support productivity and margin over time. On bookings, Ari Bousbib said strength was broad-based, with particular strength in full service and large pharma win rates, and Mike Fedock said no unusual Q4 seasonality changes were expected. On the backlog review, management said it focused on long-inactive trials, generally 18 months-plus, with no change to how backlog is recognized going forward.
The call suggested that both demand and execution are improving: clinical and commercial organic growth accelerated, bookings were strong, and management said pipelines are at record levels. AI appears to be translating into tangible customer wins and internal productivity, while management also pointed to operating leverage and margin expansion despite pass-through headwinds. The raised full-year outlook reinforces the view that the company is exiting the year with momentum.
Pass-through-heavy full-service work can pressure reported margins, and management acknowledged a roughly 70 basis point gross-margin headwind from pass-throughs. The $2.1 billion backlog adjustment shows that some work has remained inactive for a long time, even if management said it does not affect guidance or bookings trends. Management also flagged that Q4 comparisons are difficult and that the implied growth rates should not be read as a deceleration.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 94.9%
- Shares Outstanding
- 164.80M
- Float Shares
- 156.45M
of shares held by institutions
1,125 13F filers
Buy/sell ratio 0.43. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for IQV, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Kevin HernHouse · OK01 | Sell | Sep 8, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Sep 14, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Sep 3, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Sep 8, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Sep 3, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Mar 16, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 29, 26 | Filing → |
| Markwayne MullinSenate · OK | Buy | Dec 29, 25 | Filing → |
| John BoozmanSenate · AR | Sell | Oct 2, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 29, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Sell | May 15, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Buy | Apr 8, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Sell | Feb 25, 25 | Filing → |
| Markwayne MullinSenate · OK | Buy | Feb 13, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 19.65M | ▲ 159.90K |
| Blackrock, Inc. | 14.43M | ▼ 116.40K |
| Vanguard Capital Management LLC | 10.78M | ▼ 127.60K |
| Harris Associates L P | 10.44M | ▼ 1.74M |
| State Street Corp | 7.52M | ▲ 8.25K |
| Vanguard Portfolio Management LLC | 7.36M | ▼ 139.57K |
| Geode Capital Management, LLC | 4.43M | ▼ 28.64K |
| Boston Partners | 4.37M | ▼ 97.26K |
| Jpmorgan Chase & Co | 4.32M | ▼ 1.82M |
| Artisan Partners Limited Partnership | 3.46M | ▼ 1.28M |
| Invesco Ltd. | 2.94M | ▼ 331.90K |
| Morgan Stanley | 2.68M | ▼ 24.46K |
Held by 2,020 ETFs
Biggest fund positions in IQV by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 9, 26 | Sherbet Eric | other | 8,436 |
| Nov 9, 26 | Sherbet Eric | sell | 4,446 |
| Nov 9, 26 | Sherbet Eric | sell | 3,990 |
| Nov 9, 26 | Sherbet Eric | other | 8,436 |
| Nov 5, 26 | Wims Morris Leslie | other | 125 |
| Nov 5, 26 | GOGGINS COLLEEN A | other | 144 |
| Nov 5, 26 | Fasano Jim | other | 154 |
| Nov 5, 26 | DANHAKL JOHN G | other | 134 |
| Sep 2, 26 | Berkshire James G. | other | 5,381 |
| Sep 2, 26 | Berkshire James G. | sell | 2,668 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IQV coverage
Recent articles, reports, and earnings notes.

IQVIA Holdings (IQV): Growth Momentum Meets Leverage Risk
IQVIA posted 8.0% revenue growth, 11.3% EPS growth, and stronger bookings, but its 3.45x net leverage keeps the stock at Hold. The report sees solid operating momentum, yet limited margin of safety at current levels.

Clinical Research and Pharma Services Stocks That Beat Estimates: 3 Picks
A three-stock countdown explores CRO, preclinical, analytics and pharma-services exposure, with Charles River and IQVIA among the names assessed.

IQVIA Holdings Inc. (IQV) falls 13.7% after insider sales
IQVIA Holdings Inc. (IQV) falls sharply after hours after a cluster of insider sale filings, including a reported $26.1 million sale by CEO Ari Bousbib. The drop comes despite strong Q2 results and raised full-year guidance, leaving investors to weigh sentiment against solid fundamentals.
Want a deeper read on IQV?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
IQVIA Holdings Inc. $IQV Stock Holdings Increased by Eurizon Capital SGR S.p.A.
defenseworld.net · Nov 15
IQVIA Stock Jumps 59% in 6 Months: Here's What You Should Know
zacks.com · Nov 13
IQVIA Holdings Inc. $IQV Stock Holdings Decreased by CenterBook Partners LP
defenseworld.net · Nov 13
Artisan Select Equity Fund Q3 2026 Portfolio Review
seekingalpha.com · Nov 12
IQVIA: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 9
Artisan Global Value Fund Q3 2026 Portfolio Discussion
seekingalpha.com · Oct 29
Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock
zacks.com · Oct 29
IQVIA Holdings Inc. $IQV Stock Purchased by Citizens Financial Group Inc. RI
defenseworld.net · Oct 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 15, 2026 · Live quote · Not investment advice